Please login to the form below

I have forgotten my password

Perrigo

This page shows the latest Perrigo news and features for those working in and with pharma, biotech and healthcare.

As CEO returns, Valeant admits SEC probe

A lower-cost generic version from Perrigo "outsells the branded product by more than 250 to 1", it added.

Latest news

Mylan agrees to buy Sweden's Meda for $7.2bn

Deal is set to boost its over-the-counter medicines portfolio . Mylan has shrugged off the disappointment of its failed bid for Perrigo with a $7.2bn deal to merge with ... albeit not as large as would have been forthcoming with the proposed $26bn
Mylan buys into six biosimilars, including Orencia candidate

To bolster its portfolio and pipeline, Mylan mounted a hostile takeover for generic and over-the-counter (OTC) drug specialist Perrigo last year, but failed to bring the deal to a
AstraZeneca sets sights on China with Takeda deal

The company also recently sold off US rights to gastroenterology drug Entocort (budesonide) to Perrigo for $380m, saying the product lay outside its strategic focus.
Mylan misses Perrigo takeover deadline

He added that Perrigo will go ahead with a $2bn share repurchase and said the firm plans to complete $500m of that by the end of 2015. ... Shares in Mylan ended the day on Friday up 13%, while Perrigo fell around 6%.
Teva planning fresh offer for Mylan, say sources

Under chairman Robert Coury, Mylan has rebuffed all of Teva's attempts to get around the negotiating table whilst pursuing its own acquisition of an equally reluctant Perrigo, based in Ireland, ... There have been some s ignals of late however that

More from news
Approximately 9 fully matching, plus 22 partially matching documents found.

Latest Intelligence

Pharma deals continue to slide

$35bn. $7.3bn. Valeant. 40. 17.5. -56%. $28bn. ($2.4bn). Perrigo. 90. 78. ... Perrigo, like Teva and Valeant, is seeking to reduce debt. Biotech companies are also selling (or licensing) assets to stay alive.
Deal Watch February 2017

The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... 17, 900. Perrigo/ Royalty Pharma. Tysabri
Deal Watch August 2016

In contrast, in 2015 Mylan made a tender offer for Perrigo. ... Sep 15 / Hostile. Mylan. Perrigo. $26bn. Tender offer failed as Mylan shares dropped in value (Teva withdrew bid).
Deal Watch November 2015

Perrigo paid a multiple of 3.2x sales for the US rights whereas Tillotts paid 4.1x sales. ... 386. AstraZeneca. Perrigo. Acquisition - asset. Entocort (budesonide) marketed for mild to moderate Crohn's disease.
Pharma deals in August 2015

Hostile takeovers remained a topic of conversation this month as the Perrigo / Mylan saga played on; the vote taken by Mylan's shareholders on 28 August indicated support for the deal ... Perrigo had previously expressed concerns over Mylan's corporate

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

Perrigo appoints Gerresheimer’s Uwe Rohrhoff as CEO

Generic pharmaceutical company Perrigo has appointed Uwe Rohrhoff, Gerresheimer’s former chief executive officer, as its new CEO. ... Perrigo said that it suspended its search for a replacement CFO during its search for Hendrickson’s successor as CEO.
BMS appoints three independent directors

He currently serves as a director at Perrigo Company and Stamps.com, and is the former president of Capital Guardian Trust Company, and global equity portfolio manager at Capital Group.
Valeant appoints Joseph Papa to end CEO uncertainty

Valeant's month-long search for a new chief executive has ended with its selection of Perrigo's Joseph Papa to replace current CEO Michael Pearson in early May. ... He moves to Valeant from his most recent role as chief executive officer and chairman of
Perrigo promotes Neil Lister to UK leadership role

He will head up the firm's UK and Ireland business. Dublin-based Perrigo Company, has promoted Neil Lister to lead its newly-combined UK and Ireland business. ... In this role, he will be responsible for leading both the company's Omega Pharma
Keith Webber leaves FDA for Perrigo

Switches regulatory agency for biopharma company. Perrigo Company has named former US Food and Drug Administration (FDA) employee Keith Webber as head of its regulatory review process. ... The role marks a switch to the industry side of pharma for Webber,

More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest from PMHub

3 Monkeys Zeno

If you’d like to know more healthcare@3monkeyszeno.com Or visit; Merck, Bayer, Boehringher Ingelheim, Novartis, Hologic, Netflix, SilverCloud, Advanced Accelerator Applications, Perrigo.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer: Salary TBC

Medical Writer/ Senior Medical Writer opportunities – Macclesfie...: competitive salary and benefits package

Subscribe to our email news alerts

PMHub

Add my company

Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

The social dilemma: is it time for pharma to join the party?: Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin: A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
25 Women Leaders in UK Healthcare: Women trailblazers helping to shape the future of healthcare (Part 1)...